Entera Bio Ltd. Shares (Basic, Weighted)

Shares (Basic, Weighted) of ENTX for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shares (Basic, Weighted) growth rates and interactive chart. Number of basic weighted average common shares outstanding in a company.


Highlights and Quick Summary

  • Shares (Basic, Weighted) for the quarter ending September 29, 2020 was $18.3 Million (a 0.53% increase compared to previous quarter)
  • Year-over-year quarterly Shares (Basic, Weighted) increased by 50.9%
  • Annual Shares (Basic, Weighted) for 2019 was $12.1 Million (a 52.7% increase from previous year)
  • Annual Shares (Basic, Weighted) for 2018 was $7.96 Million (a 77.13% increase from previous year)
Visit stockrow.com/ENTX for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shares (Basic, Weighted) of Entera Bio Ltd.

Most recent Shares (Basic, Weighted)of ENTX including historical data for past 10 years.

Interactive Chart of Shares (Basic, Weighted) of Entera Bio Ltd.

Entera Bio Ltd. Shares (Basic, Weighted) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $18.33 $18.23 $18.05
2019 $12.15 $12.05 $11.74 $11.46 $12.15
2018 $15.69 $11.28 $4.49 $4.49 $7.96
2017 $4.49

Business Profile of Entera Bio Ltd.

Sector: Healthcare
Industry: Biotechnology
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, an oral parathyroid hormone product candidate, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that is in Phase II clinical trials for the treatment of osteoporosis. It is also developing EB613 for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. The company was founded in 2009 and is based in Jerusalem, Israel.